Alnylam Pharmaceuticals (ALNY) Inventory Average (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has 9 years of Inventory Average data on file, last reported at $90.6 million in Q2 2026.

• Quarterly Inventory Average rose 31.96% year-over-year to $90.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $90.6 million (up 31.96% YoY) and the FY2025 annual result came in at $80.6 million, down 3.83% from the prior year.
• Inventory Average grew to $90.6 million in Q2 2026, from $83.4 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $130.4 million in Q1 2023 to a low of $68.6 million in Q2 2025.
• A 5-year average of $90.7 million and a median of $86.4 million in 2022 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2023 — Inventory Average surged 58.2% — and 2024, when it dropped 29.79%.
• Tracing ALNY's Inventory Average over 5 years: stood at $122.2 million in 2022, then decreased by 24.35% to $92.5 million in 2023, then declined by 16.45% to $77.2 million in 2024, then advanced by 2.33% to $79.1 million in 2025, then rose by 14.57% to $90.6 million in 2026.
• The last three Inventory Average figures came in at $90.6 million (Q2 2026), $83.4 million (Q1 2026), and $79.1 million (Q4 2025), per Business Quant data.